April 2014
Volume 55, Issue 13
ARVO Annual Meeting Abstract  |   April 2014
Micropulse Laser Therapy For The Treatment Of Longstanding Refractory Pseudophakic Cystoid Macular Edema
Author Affiliations & Notes
  • Joao Guilherme Aguirre
    Instituto Reynaldo Rezende, Ribeirao Preto, Brazil
    HOIP, Araraquara, Brazil
  • Alessandro J R Dare
    HOIP, Araraquara, Brazil
    CRV, Ribeirao Preto, Brazil
  • Footnotes
    Commercial Relationships Joao Guilherme Aguirre, None; Alessandro Dare, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 6356. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Joao Guilherme Aguirre, Alessandro J R Dare; Micropulse Laser Therapy For The Treatment Of Longstanding Refractory Pseudophakic Cystoid Macular Edema. Invest. Ophthalmol. Vis. Sci. 2014;55(13):6356.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: To report the functional and anatomic outcomes of a new therapeutic possibility using micropulse laser therapy (MLT) for the treatment of longstanding refractory pseudophakic cystoid macular edema (PCME).

Methods: Five eyes of four patients with PCME with duration longer than 12 months refractory to topical nonsteroidal anti-inflammatory drugs or topical corticosteroids, unsuccessfully treated with subtenon triamcinolone or intravitreal bevacizumab were subjected to high density micropulse laser therapy involving the macular area. Main outcomes were change in ETDRS best correct visual acuity (BCVA) and central macular thickness (CMT) measured using optical coherence tomography. Patients were followed 1, 2, 3, and 6-months after treatment. Pre and post-treatment fluorescein angiography (FA) were assessed.

Results: No visible clinical signs of treatment could be detected either on fundus examination or FA. By 6 months of follow-up there were full resolution of the macular edema and restoration of the foveal depression in 4 of the 5 patients. BCVA changed from 0,87 ± 0,12 logMAR to 0,62 ± 0,23 logMAR (mean ± SD) and CMT from 632 ± 86 μm to 378 ± 88 μm (mean ± SD). No complication was related to the procedure.

Conclusions: Chronic PCME is traditionally a difficult condition to treat, but we are encouraged by the optimal response experienced with micropulse laser therapy in these patients whose longstanding PCME had been refractory to previous treatments with both subtenon triamcinolone and intravitreal bevacizumab.

Keywords: 578 laser • 585 macula/fovea • 505 edema  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.